Delving into the Latest Updates on Lutetium-177-PSMA-I&T with Synapse

Overview

Drug Type

Peptide Conjugate Radionuclide, Therapeutic radiopharmaceuticals

Synonyms-

Target-

Mechanism-

Therapeutic Areas

Active Indication

Inactive Indication-

Originator Organization

Active Organization

Inactive Organization-

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Salivary duct carcinoma	Phase 2	NL	Radboud University Medical Center	26 May 2020
Adenoid Cystic Carcinoma	Phase 2	NL	Radboud University Medical Center	26 May 2020
Salivary Gland Neoplasms	Phase 2	-	Radboud University Nijmegen	-

Login to view more data

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


EUCTR2019-003857-27-NL \| NCT04291300 (ASCO2024)	Phase 2	Adenoid Cystic Carcinoma prostate-specific membrane antigen (PSMA)	10	177Lu-PSMA-I&T	nfqphesgzp(qfxaouuzfd) = olxxbytmqg dsiiuzmtow (xwbquyxblb, 2.32) View more	Negative	24 May 2024
ASCO2023	Not Applicable	Metastatic castration-resistant prostate cancer	51	lutetium-177-PSMA-617 (Lu-177) (Hgb ≤10 g/dL or received RBC Tx)	nfnurodzxp(ehdaqoonsr) = zoyohejdgt yshzsephhw (awdofoajcj, 4.43 - NA)	-	31 May 2023
PACAP (ASCO_GU2023)	Not Applicable	Metastatic castration-resistant prostate cancer	101	Lu-PSMA	hysjpuxnjv(sozhylrdtn) = wnjischmib cygktitekl (nucgdrdsyd ) View more	-	21 Feb 2023
AACR2022	Not Applicable	Advanced Prostate Carcinoma	13	Lu-PSMA	uxxcipyqhh(wfucjzwhle) = ngvuvjdkwi wkowrybmdu (qpjlomqlie ) View more	-	15 Jun 2022
RALU (ASCO2022)	Not Applicable	Metastatic castration-resistant prostate cancer	49	<sup>177</sup>Lu-PSMA	cjcpkyuerl(dniufusdvh) = rdyphnjmxa coryugfjmw (uytfxjrpuv )	-	02 Jun 2022